Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

Matza, Louis S.; Cutts, Katelyn; Stewart, Katie D.; Norrbacka, Kirsi; García‐Pérez, Luis‐Emilio; Boye, Kristina S.

doi:10.1007/s11136-021-02808-2

Cited by 11 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most frequently preferred treatment regimen was the LAI ART administered every two months. This result adds to previously reported findings suggesting that oral medication is not always preferred over injectable treatment options [ 30 ]. Current findings suggest that the LAI dose frequency of every two months is a welcome treatment option for many PLHIV, while other respondents were resistant to injections.…”

Section: Discussionsupporting

confidence: 78%

“…Mean utility differences between health states were relatively small, which is common for treatment process utilities [ 29 , 30 , 47 , 48 ]. Still, small utility differences can have an impact on the outcome of an economic model.…”

Section: Discussionmentioning

confidence: 99%

“…Research on “treatment process utilities” has shown that treatment characteristics like route of administration and dose frequency have an impact on preference and utility [ 29 , 30 ]. It is often useful to include these utilities in CUAs to better represent the experience of people receiving treatment.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV

et al. 2022

Self Cite

View full text Add to dashboard Cite

Purpose People living with HIV (PLHIV) have reported challenges associated with daily oral antiretroviral therapy (ART), including missed doses, negative psychological impact, and difficulty remaining discreet while at home or traveling. Recently approved long-acting injectable (LAI) ART may help eliminate these concerns. The purpose of this study was to examine patient preferences and estimate health state utilities associated with oral and LAI treatment for ART. Methods Four health state vignettes were developed based on published literature, clinician interviews, and a pilot study. All vignettes included the same description of HIV, but differed in treatment regimens: (A) single daily oral tablet, (B) two daily oral tablets, (C) injections once monthly, and (D) injections every two months. PLHIV in the UK reported their preferences and valued the health states in time trade-off utility interviews. Results The sample included 201 PLHIV (83.1% male; mean age = 44.9y). The health states frequently selected as most preferable were D (n = 119; 59.2%) and A (n = 75; 37.3%). Utility differences among health states were relatively small, which is typical for treatment process utilities (mean utilities: A, 0.908; B, 0.905; C, 0.900; D, 0.910). Statistically significant differences in utility were found for one vs. two tablets and injections every month vs. every two months (p < 0.001). Participants’ quotations highlight the wide range of reasons for treatment process preferences. Conclusions Current results indicate that many PLHIV would prefer LAI ART. The reported utilities may be useful in economic modeling comparing oral vs. LAI ART.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“… 47 Matza et al reported that nearly half of patients with T2DM prefer injectable to oral treatment if the former can be administered weekly instead of daily with oral treatment. 27 In oncology, Mansfield et al demonstrated that patients may prefer an IV schedule to oral treatment if the latter requires several pills a day or a complicated dosing schedule. 48 …”

Section: Discussionmentioning

confidence: 99%

Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China

Hu,

Wu,

et al. 2023

PROM

View full text Add to dashboard Cite

Purpose Treatment process attributes can affect health state utilities associated with therapy. For intravenous iron, used to treat iron deficiency and iron deficiency anemia, research into process attributes is still lacking. This study estimated utilities associated with process attributes for intravenous iron infusions. Methods An online survey including seven health state vignettes and time trade-off tasks was administered to participants, who were not patients living with iron deficiency or iron deficiency anemia, from a Chinese online panel. Vignettes used an identical description of iron deficiency and iron deficiency anemia but differed in the annual number of infusions, infusion duration, and infusion-associated risk of hypophosphatemic osteomalacia. Disutilities and their rate of change as the number of infusions increased were examined using a power model. Results The survey was completed by 1091 participants. The highest utilities were observed for one annual infusion of 15–30 minutes or 30–60 minutes, without risk of hypophosphatemic osteomalacia (0.754 and 0.746, respectively). In comparison, more infusions and infusions with a risk of hypophosphatemic osteomalacia were associated with lower utilities. Utility continued to decrease, but at a diminishing rate, as the annual number of infusions increased, with utility decrements of 0.006 and 0.002, respectively, when going from zero to one and from four to five infusions per year. All marginal disutilities were small (values <0.01). Conclusion This study suggested that treatment attributes of intravenous iron infusions affect health state utilities. Using intravenous iron formulations that allow for fewer and shorter infusions without the risk of hypophosphatemic osteomalacia can reduce the number of visits required and increase patients’ quality of life.

show abstract

“…Following the VAS exercises, TTO exercises were conducted for each health state. Each TTO exercise comprised questions prompting the participants to select between x years in full health, and 20 years in the health state (rather than 10 years within the MVH protocol, as per published outcomes research in T2DM) [ 18 , 27 ]. At each step, if a participant selected full health, x was decreased, and if a participant selected the health state, x was increased.…”

Section: Methodsmentioning

confidence: 99%

Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China

et al. 2022

View full text Add to dashboard Cite

Introduction Once-daily and once-weekly injectable glucagon-like peptide-1 receptor agonist therapies (GLP-1 RAs) are established in obesity and type 2 diabetes mellitus (T2DM). In T2DM, both once-daily and once-weekly insulin are expected to be available. This study elicited utilities associated with these treatment regimens from members of the general public in the UK, Canada, and China, to quantify administration-related disutility of more-frequent injectable treatment, and allow economic modelling. Methods Two anchor states (no pharmacological treatment), and seven treatment states (daily oral tablet and generic injectable regimens of variable frequency), with identical outcomes were tested A broadly representative sample of the general public in each country participated (excluding individuals with diabetes or pharmacologically treated obesity). An adapted Measurement and Valuation of Health protocol was administered 1:1 in web-enabled interviews by trained moderators: visual analogue scale (VAS) as a “warm-up”, and time trade-off (TTO) using a 20-year time horizon for utility elicitation. Results A total of 310 individuals participated. The average disutility of once-daily versus once-weekly GLP-1 RA was − 0.048 in obesity and − 0.033 in T2DM; the corresponding average disutility for insulin was − 0.064. Disutilities were substantially greater in China, relative to UK and Canada. Discussion Within obesity and T2DM, more-frequent treatment health states had lower utility. Scores by VAS also followed a logical order. The generated utility values are suitable for use in modelling injectable therapy regimens in obesity and T2DM, due to the use of generic descriptions and assumption of equal efficacy. Future research could examine the reasons for greater administration-related disutility in China.

show abstract

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

Cited by 11 publications

References 35 publications

Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV

Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV

Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China

Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China

Contact Info

Product

Resources

About